

○ XF assay medium 조성

XF DMEM (50 mL)	XF RPMI (50 mL)
D-glucose 1.25 mL	D-glucose 560 μL
Pyruvate 630 μL	Glutamate 520 μL
Glutamate 1 mL	

○ MST kit dilution method


Compound	Volume (XF assay medium)	Stock Conc
Oligomycin	630 μL	100 μM
FCCP	720 μL	100 μM
Rotenon/AA	540 μL	50 μM

○ Glycolytic Rate kit dilution method

Compound	Volume (XF assay medium)	Stock Conc
Rotenon/AA	540 μL	50 μM
2-DG	3,000 μL	500 mM

○ Real-Time ATP kit dilution method

Compound	Volume (XF assay medium)	Stock Conc
Oligomycin	420 μL	150 μM
Rotenon/AA	540 μL	50 μM



Mito Stress Test	최종농도 (μM) (per well)	Stock Solution Volume (μL)	Media Volume (μL)	10X 농도 (Port) (μM)	Volume added to port (μL)	Port A에 drug (20 μL) 처리시
Oligomycin (Port A)	0.5	150	2,850	5.0	20	22 (Port B)
	1.5	450	2,550	15	20	
	2.0	600	2,400	20	20	
	2.5	630	1,890	25	20	
FCCP (Port B)	0.125	37.5	2,962.5	1.25	22	25 (Port C)
	0.25	75	2,925	2.5	22	
	0.5	150	2,850	5.0	22	
	1.0	300	2,700	10	22	
	2.0	600	2,400	20	22	
Rotenon/AA + Hoechst 3 μL (10 mM) (Port C)	0.5	300	2,700	5.0	25	27 (Port D)

Glycolytic Rate Test	최종농도 (per well)	Stock Solution Volume (μL)	Media Volume (μL)	10X 농도 (Port)	Volume added to port (μL)	Port A에 drug (20 μL) 처리시
Rotenon/AA (Port A)	0.5 (μM)	300	2,700	5.0 (μM)	20	22 (Port B) or 25 (Port C)_A,B에 drug 처리시
2-DG + Hoechst 3 μL (10 mM) (Port B)	50 (mM)	3,000	0	500 (mM)	22	25 (Port C) or 27 (Port D)_A, B에 drug 처리시

Real-Time ATP Test	최종농도 (μM) (per well)	Stock Solution Volume (μL)	Media Volume (μL)	10X 농도 (Port) (μM)	Volume added to port (μL)	Port A에 drug (20 μL) 처리시
Oligomycin (Port A)	1.5	300	2,700	15	20	22 (Port B) or 25 (Port C)_A,B에 drug 처리시
Rotenon/AA + Hoechst 3 μL (10 mM) (Port B)	0.5	300	2,700	5.0	22	25 (Port C) or 27 (Port D)_A, B에 drug 처리시